NAION Risk Factors: Who May Need a More Individualized GLP-1 Discussion?

A Medication Is Only One Part of the Risk Picture

When patients hear that GLP-1 medications may be associated with NAION, it is easy to focus on the prescription as the only variable.

But NAION existed long before semaglutide. As we discuss in our complete guide to GLP-1 medications and NAION, many people who benefit from these treatments also have medical conditions that independently affect vascular or optic nerve health.

That overlap is one reason the conversation is medically complex—and one reason patients in Hampton Roads deserve an individualized answer rather than a broad warning based on a drug name.

Established and Suspected NAION Risk Factors

Factors associated with NAION include:

• Age, especially over 50

• Type 2 diabetes

• High blood pressure

• High cholesterol

• Obstructive sleep apnea

• Cardiovascular or cerebrovascular disease

• Smoking

• Certain optic nerve anatomy

• A previous episode of NAION

The anatomy deserves explanation. Some people have a relatively small or crowded optic nerve head with little or no visible cup. Clinicians sometimes call this a “disc at risk.” It does not mean NAION is inevitable. It means the structure of the nerve may leave less room to accommodate swelling if circulation becomes impaired.

Australia’s 2026 safety update specifically noted that people with this anatomical predisposition are at the highest baseline risk of NAION, whether or not they take a GLP-1 medication.

Three Patients, Three Different Conversations

Consider three simplified scenarios:

Patient A: Diabetes Without Known Optic Nerve Disease

This patient uses semaglutide, has controlled blood pressure, receives regular diabetic eye examinations and has no history of NAION. The conversation may focus on awareness of symptoms, routine eye care and the overall benefits and risks of treatment.

Patient B: Several Modifiable Risk Factors

This patient has diabetes, untreated sleep apnea, high blood pressure and smokes. The discussion should not be limited to whether to continue one medication. Treating sleep apnea, controlling blood pressure, improving cholesterol management and stopping smoking may matter to the patient’s overall vascular health.

Patient C: Previous NAION

This patient has already experienced NAION in one eye and is considering a GLP-1 medication. That history raises a different level of concern. The prescribing clinician and eye care team should discuss the indication for treatment, alternatives, optic nerve findings, systemic risk factors and the importance of the remaining eye.

These examples are not treatment rules. They illustrate why identical prescriptions do not create identical risk discussions.

What Should You Tell Your Physicians?

Before starting or reviewing a GLP-1 medication, make sure your care team knows about:

• Previous NAION or unexplained sudden vision loss

• Known optic nerve disease

• Diabetes and recent changes in blood-sugar control

• High blood pressure or high cholesterol

• Diagnosed or suspected sleep apnea

• Cardiovascular or cerebrovascular disease

• Smoking

• All prescription and nonprescription medications

This information does not automatically disqualify a patient from treatment. It improves the quality of the decision.

If you are uncertain which visual changes require urgent care, review NAION Symptoms: When Sudden Vision Loss Requires Urgent Care.

Should High-Risk Patients Get an Eye Exam?

There is no single screening protocol that predicts every case of NAION. However, an ophthalmic examination can document existing eye disease and optic nerve anatomy and may help inform a discussion for someone with previous NAION or multiple risk factors.

The purpose is perspective, not a guarantee.

At Wagner Kapoor Institute, our ophthalmologists provide specialty eye care for patients in Virginia Beach and across Hampton Roads. To discuss an ophthalmic evaluation, call 757-481-4400.

Related reading

• GLP-1 Medications and NAION: Full Guide

• NAION Symptoms and Sudden Vision Loss

• Does Ozempic Cause Vision Loss?

Sources

• American Academy of Ophthalmology clinical statement on GLP-1 receptor agonists and NAION

• Risk factors for NAION: systematic review and meta-analysis, Frontiers in Medicine

• Australian TGA: GLP-1 RAs and rare vision disorder (2026)

Author

Kapil G. Kapoor, MD, FACS, FICS, FASRS Dr. Kapil G. Kapoor, is a board certified ophthalmologist specializing in vitreoretinal surgery. He is Co-Founder and President of the Wagner Kapoor Research Institute which has been actively engaged in over 75 clinical trials, often one of the only sites in the region offering sight-saving treatment. He has been passionately involved in ophthalmology research as part of his mission to deliver the best care possible to his patients. With over a decade’s experience in the field, Dr. Kapoor is a progressive leader in the healthcare space.